Xenetic Biosciences posted a GAAP net loss of USD 929,695 for the quarter ended June 30, 2026, widening 35% year over year.
Revenue rose 12% to USD 660,601, driven by higher royalty revenue tied to its Takeda sublicense in certain countries.
Operating loss widened 34.1% to USD 971,690 as total operating costs and expenses climbed 24.2% to USD 1.63 million.
R&D expense fell 15.9% to USD 552,013, while G&A jumped 64.2% to USD 1.08 million on higher legal costs tied to a strategic review.
The board is running a formal strategic review that includes options such as an asset sale or reverse merger, while continuing to advance its systemic DNase program.
XBIO•
